BIIB vs. LLY
Compare and contrast key facts about Biogen Inc. (BIIB) and Eli Lilly and Company (LLY).
Performance
BIIB vs. LLY - Performance Comparison
Loading graphics...
BIIB vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 4.17% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Fundamentals
BIIB:
$26.89B
LLY:
$825.96B
BIIB:
$8.82
LLY:
$22.96
BIIB:
20.77
LLY:
40.06
BIIB:
1.44
LLY:
0.81
BIIB:
2.74
LLY:
12.68
BIIB:
1.47
LLY:
31.13
BIIB:
$9.81B
LLY:
$65.18B
BIIB:
$6.91B
LLY:
$54.62B
BIIB:
$3.10B
LLY:
$27.94B
Returns By Period
In the year-to-date period, BIIB achieves a 4.17% return, which is significantly higher than LLY's -14.27% return. Over the past 10 years, BIIB has underperformed LLY with an annualized return of -3.45%, while LLY has yielded a comparatively higher 30.92% annualized return.
BIIB
- 1D
- -2.26%
- 1M
- -4.43%
- YTD
- 4.17%
- 6M
- 30.88%
- 1Y
- 33.97%
- 3Y*
- -12.96%
- 5Y*
- -8.04%
- 10Y*
- -3.45%
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIIB vs. LLY — Risk / Return Rank
BIIB
LLY
BIIB vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIIB | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 0.29 | +0.70 |
Sortino ratioReturn per unit of downside risk | 1.63 | 0.69 | +0.94 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.10 | +0.09 |
Calmar ratioReturn relative to maximum drawdown | 1.90 | 0.42 | +1.48 |
Martin ratioReturn relative to average drawdown | 4.80 | 1.02 | +3.77 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIIB | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 0.29 | +0.70 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.21 | 1.23 | -1.44 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.08 | 1.04 | -1.12 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.56 | -0.34 |
Correlation
The correlation between BIIB and LLY is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BIIB vs. LLY - Dividend Comparison
BIIB has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
BIIB vs. LLY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -89.98%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for BIIB and LLY.
Loading graphics...
Drawdown Indicators
| BIIB | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.98% | -68.24% | -21.74% |
Max Drawdown (1Y)Largest decline over 1 year | -14.13% | -30.26% | +16.13% |
Max Drawdown (5Y)Largest decline over 5 years | -72.66% | -34.48% | -38.18% |
Max Drawdown (10Y)Largest decline over 10 years | -72.66% | -34.48% | -38.18% |
Current DrawdownCurrent decline from peak | -61.48% | -17.00% | -44.48% |
Average DrawdownAverage peak-to-trough decline | -36.48% | -19.25% | -17.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.78% | 12.39% | -5.61% |
Volatility
BIIB vs. LLY - Volatility Comparison
Biogen Inc. (BIIB) and Eli Lilly and Company (LLY) have volatilities of 8.91% and 9.04%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIIB | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.91% | 9.04% | -0.13% |
Volatility (6M)Calculated over the trailing 6-month period | 24.16% | 26.21% | -2.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.48% | 42.44% | -7.96% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.11% | 32.14% | +5.97% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.40% | 29.80% | +11.60% |
Financials
BIIB vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIIB vs. LLY - Profitability Comparison
BIIB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a gross profit of 1.78B and revenue of 2.28B. Therefore, the gross margin over that period was 78.2%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.
BIIB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported an operating income of -57.00M and revenue of 2.28B, resulting in an operating margin of -2.5%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.
BIIB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a net income of -48.41M and revenue of 2.28B, resulting in a net margin of -2.1%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.